Titan Pharma: Up as partner signs distribution deal for opioid addiction drug

Titan Pharmaceuticals

15/09/2020 17:08

** Drugmaker's shares  TTNP.O  rise 19% to $0.22
    ** Co's partner, Molteni, enters into exclusive distribution
agreement with Accord Healthcare Europe for commercialization of
Probuphine, sold under brand name of Sixmo, in EU  urn:newsml:reuters.com:*:nPn41G4LFa
    ** Sixmo is an implant for long-term maintenance treatment
of opioid dependence; it was approved for U.S. sales in 2016
    ** TTNP entitled to about $1.1 mln in future milestone
payments and royalty payments on net sales of Sixmo, commencing
in H2 2021
    ** Stock up ~16% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))